In a nutshell This study aimed to investigate the long-term outcomes of venetoclax and rituximab (VR) treatment in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL). This study concluded that this treatment had long-term effectiveness in these patients. Some background Bendamustine...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Blinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia
In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL). This study concluded that both treatments are safe and effective as a...
Read MoreSearching for patients with non-small cell lung cancer to trial a treatment combination
In a nutshell This trial is looking to examine the effectiveness of carboplatin (Paraplatin), paclitaxel (Taxol), and ramucirumab (Cyramza) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) that is progressive after maintenance therapy. The main outcome that is to be measured is the response of the...
Read MoreLong-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL
In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these patients. Some background...
Read MoreLong-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL
In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma. This study concluded that this combination was safe and effective in the long-term in these...
Read MoreEvaluating low-dose pembrolizumab and nivolumab for relapsed or refractory classical Hodgkin lymphoma.
In a nutshell This trial was carried out to examine the effectiveness and safety profile of pembrolizumab (Keytruda) and nivolumab (Opdivo) for the treatment of classical Hodgkin lymphoma (cHL) that has relapsed and is refractory (resistant to drug treatment). The authors found that...
Read MoreDoes a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...
Read MoreLooking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination
In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....
Read MoreMTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma
In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...
Read MoreComparing salvage regimes for patients with relapsed/refractory acute myeloid leukemia
In a nutshell This study aimed to compare two salvage regimes for patients with relapsed/refractory acute myeloid leukemia. This study concluded that both regimens have similar effectiveness in terms of overall response but one shows a significant reduction in side effects in these patients. Some background...
Read MoreAbemaciclib plus trastuzumab for advanced HER-2 positive breast cancer
In a nutshell This study looked at abemaciclib (Verzenio), trastuzumab (Herceptin), and fulvestrant (Faslodex) for the treatment of advanced hormone-receptor-positive (HR+) and HER2 positive (HER2+) breast cancer. It found that this treatment led to better outcomes than standard-of-care chemotherapy for these patients. Some background Worldwide,...
Read MoreThe benefits of repeated cytoreductive surgery and hyperthermic peritoneal chemotherapy in advanced colorectal cancer
In a nutshell This study investigated the benefits of repeated cytoreductive surgery (CRS) and hyperthermic peritoneal chemotherapy (HIPEC) in patients with advanced colorectal cancer. Researchers suggested that repeated treatment improves the survival of patients with advanced colorectal cancer, without an increase in side effects. Some background...
Read More